David Allan Butterfield

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8738690/publications.pdf

Version: 2024-02-01

448 papers

44,953 citations

952 115 h-index 2953 189 g-index

458 all docs

458 docs citations

458 times ranked

36469 citing authors

#	Article	IF	CITATIONS
1	Altered Metabolism in Alzheimer Disease Brain: Role of Oxidative Stress. Antioxidants and Redox Signaling, 2022, 36, 1289-1305.	5.4	39
2	Oxidative stress and mTOR in Down syndrome brain: Link to Alzheimer's dysmetabolism, neuropathology, and possible therapies. , 2022, , 75-96.		0
3	Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronalâ€derived extracellular vesicles. Alzheimer's and Dementia, 2022, 18, 1498-1510.	0.8	16
4	Metabolic Features of Brain Function with Relevance to Clinical Features of Alzheimer and Parkinson Diseases. Molecules, 2022, 27, 951.	3.8	12
5	CAPE and its synthetic derivative VP961 restore BACH1/NRF2 axis in Down Syndrome. Free Radical Biology and Medicine, 2022, 183, 1-13.	2.9	9
6	Extracellular vesicles released after cranial radiation: An insight into an early mechanism of brain injury. Brain Research, 2022, 1782, 147840.	2.2	5
7	Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention. Progress in Neurobiology, 2021, 196, 101892.	5.7	21
8	Fidelity of the PINK1 knockout rat to oxidative stress and other characteristics of Parkinson disease. Free Radical Biology and Medicine, 2021, 163, 88-101.	2.9	9
9	Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome. Free Radical Biology and Medicine, 2021, 165, 152-170.	2.9	26
10	Assessment of chemotherapy-induced cognitive impairment: A prospective study of the biochemical and metabolic effects of platinum/taxane-based chemotherapy in gynecologic cancer patients Journal of Clinical Oncology, 2021, 39, e24051-e24051.	1.6	0
11	The preparation temperature influences the physicochemical nature and activity of nanoceria. Beilstein Journal of Nanotechnology, 2021, 12, 525-540.	2.8	O
12	Chemotherapy-induced cognitive impairment: focus on the intersection of oxidative stress and TNF $\hat{l}\pm$. Cellular and Molecular Life Sciences, 2021, 78, 6533-6540.	5.4	9
13	Healthy dietary intake moderates the effects of age on brain iron concentration and working memory performance. Neurobiology of Aging, 2021, 106, 183-196.	3.1	12
14	The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radical Biology and Medicine, 2021, 176, 16-33.	2.9	53
15	Ubiquitin carboxyl-terminal hydrolase L-1 in brain: Focus on its oxidative/nitrosative modification and role in brains of subjects with Alzheimer disease and mild cognitive impairment. Free Radical Biology and Medicine, 2021, 177, 278-286.	2.9	12
16	Insufficient Sun Exposure Has Become a Real Public Health Problem. International Journal of Environmental Research and Public Health, 2020, 17, 5014.	2.6	71
17	The BACH1/Nrf2 Axis in Brain in Down Syndrome and Transition to Alzheimer Disease-Like Neuropathology and Dementia. Antioxidants, 2020, 9, 779.	5.1	21
18	Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease. Antioxidants, 2020, 9, 818.	5.1	42

#	Article	IF	Citations
19	Nanoceria distribution and effects are mouse-strain dependent. Nanotoxicology, 2020, 14, 827-846.	3.0	11
20	Brain lipid peroxidation and alzheimer disease: Synergy between the Butterfield and Mattson laboratories. Ageing Research Reviews, 2020, 64, 101049.	10.9	45
21	APOE in Alzheimer's disease and neurodegeneration. Neurobiology of Disease, 2020, 139, 104847.	4.4	5
22	Loss of CLN3, the gene mutated in juvenile neuronal ceroid lipofuscinosis, leads to metabolic impairment and autophagy induction in retinal pigment epithelium. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165883.	3.8	24
23	Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease. Neurobiology of Disease, 2020, 138, 104795.	4.4	100
24	Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. Neurobiology of Disease, 2020, 137, 104772.	4.4	54
25	Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease. Molecular Neurobiology, 2019, 56, 2922-2943.	4.0	70
26	Profiles of brain oxidative damage, ventricular alterations, and neurochemical metabolites in the striatum of PINK1 knockout rats as functions of age and gender: Relevance to Parkinson disease. Free Radical Biology and Medicine, 2019, 143, 146-152.	2.9	16
27	Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives. CNS Drugs, 2019, 33, 957-969.	5.9	45
28	Extracellular vesicle-mediated macrophage activation: An insight into the mechanism of thioredoxin-mediated immune activation. Redox Biology, 2019, 26, 101237.	9.0	19
29	mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation. Transplantation, 2019, 103, 705-715.	1.0	28
30	Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome. Redox Biology, 2019, 23, 101162.	9.0	46
31	Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nature Reviews Neuroscience, 2019, 20, 148-160.	10.2	1,021
32	Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease. Neurobiology of Disease, 2019, 125, 176-189.	4.4	55
33	Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment ("chemobrainâ€), a condition that significantly impairs the quality of life of many cancer survivors. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1088-1097.	3.8	75
34	Redox proteomics and amyloid βâ€peptide: insights into Alzheimer disease. Journal of Neurochemistry, 2019, 151, 459-487.	3.9	80
35	Phosphoproteomics of Alzheimer disease brain: Insights into altered brain protein regulation of critical neuronal functions and their contributions to subsequent cognitive loss. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2031-2039.	3.8	10
36	The triangle of death of neurons: Oxidative damage, mitochondrial dysfunction, and loss of choline-containing biomolecules in brains of mice treated with doxorubicin. Advanced insights into mechanisms of chemotherapy induced cognitive impairment ("chemobrainâ€) involving TNF-α. Free Radical Biology and Medicine, 2019, 134, 1-8.	2.9	59

#	Article	IF	Citations
37	Disruption of the hippocampal and hypothalamic blood–brain barrier in a diet-induced obese model of type II diabetes: prevention and treatment by the mitochondrial carbonic anhydrase inhibitor, topiramate. Fluids and Barriers of the CNS, 2019, 16, 1.	5.0	106
38	Perspectives on Oxidative Stress in Alzheimer's Disease and Predictions of Future Research Emphases. Journal of Alzheimer's Disease, 2018, 64, S469-S479.	2.6	41
39	Oxidative Stress, Amyloid-β Peptide, and Altered Key Molecular Pathways in the Pathogenesis and Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1345-1367.	2.6	271
40	Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism. Free Radical Biology and Medicine, 2018, 114, 84-93.	2.9	38
41	Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury. Clinical Cancer Research, 2018, 24, 1644-1653.	7.0	54
42	Down syndrome: From development to adult life to Alzheimer disease. Free Radical Biology and Medicine, 2018, 114, 1-2.	2.9	6
43	mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia. Free Radical Biology and Medicine, 2018, 114, 94-101.	2.9	72
44	Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. Translational Neurodegeneration, 2018, 7, 28.	8.0	76
45	Microdose Lithium NPO3 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat Model of Alzheimer's-like Amyloidosis. Current Alzheimer Research, 2018, 15, 1220-1230.	1.4	18
46	Protein nitration profile of CD3+ lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection. Free Radical Biology and Medicine, 2018, 129, 430-439.	2.9	20
47	Biliverdin reductase-A impairment links brain insulin resistance with increased $\hat{Al^2}$ production in an animal model of aging: Implications for Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3181-3194.	3.8	49
48	Poly-ubiquitin profile in Alzheimer disease brain. Neurobiology of Disease, 2018, 118, 129-141.	4.4	29
49	Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3309-3321.	3.8	29
50	Doxorubicin-induced elevated oxidative stress and neurochemical alterations in brain and cognitive decline: protection by MESNA and insights into mechanisms of chemotherapy-induced cognitive impairment ("chemobrainâ€). Oncotarget, 2018, 9, 30324-30339.	1.8	102
51	Oxidative stress, protein modification and Alzheimer disease. Brain Research Bulletin, 2017, 133, 88-96.	3.0	230
52	Dysregulation of cytokine mediated chemotherapy induced cognitive impairment. Pharmacological Research, 2017, 117, 267-273.	7.1	66
53	Oxidative stress and neurodegeneration. Brain Research Bulletin, 2017, 133, 1-3.	3.0	9
54	Temperature induces significant changes in both glycolytic reserve and mitochondrial spare respiratory capacity in colorectal cancer cell lines. Experimental Cell Research, 2017, 354, 112-121.	2.6	24

#	Article	IF	Citations
55	The role of charge in the toxicity of polymer-coated cerium oxide nanomaterials to Caenorhabditis elegans. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2017, 201, 1-10.	2.6	12
56	Acute treatment with doxorubicin affects glutamate neurotransmission in the mouse frontal cortex and hippocampus. Brain Research, 2017, 1672, 10-17.	2.2	53
57	Redox Proteomics: A Key Tool for New Insights into Protein Modification with Relevance to Disease. Antioxidants and Redox Signaling, 2017, 26, 277-279.	5.4	34
58	HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology. Free Radical Biology and Medicine, 2017, 111, 262-269.	2.9	41
59	Comparative proteomic analyses of the parietal lobe from rhesus monkeys fed a high-fat/sugar diet with and without resveratrol supplementation, relative to a healthy diet: Insights into the roles of unhealthy diets and resveratrol on function. Journal of Nutritional Biochemistry, 2017, 39, 169-179.	4.2	8
60	Blockade of Glutamine Synthetase Enhances Inflammatory Response in Microglial Cells. Antioxidants and Redox Signaling, 2017, 26, 351-363.	5.4	61
61	Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders. Free Radical Biology and Medicine, 2017, 111, 253-261.	2.9	190
62	Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Expert Review of Neurotherapeutics, 2017, 17, 59-75.	2.8	29
63	The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics. Antioxidants and Redox Signaling, 2017, 26, 364-387.	5. 4	97
64	Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology. Antioxidants and Redox Signaling, 2017, 26, 280-298.	5.4	38
65	It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-12.	4.0	88
66	Reaching Out to Send a Message: Proteins Associated with Neurite Outgrowth and Neurotransmission are Altered with Age in the Long-Lived Naked Mole-Rat. Neurochemical Research, 2016, 41, 1625-1634.	3.3	7
67	Lipid peroxidation and tyrosine nitration in traumatic brain injury: Insights into secondary injury from redox proteomics. Proteomics - Clinical Applications, 2016, 10, 1191-1204.	1.6	19
68	Controlled curcumin release via conjugation into PBAE nanogels enhances mitochondrial protection against oxidative stress. International Journal of Pharmaceutics, 2016, 511, 1012-1021.	5.2	22
69	In Vitro Cellular Assays for Oxidative Stress and Biomaterial Response., 2016,, 145-186.		5
70	Effect of botanical extracts containing carnosic acid or rosmarinic acid on learning and memory in SAMP8 mice. Physiology and Behavior, 2016, 165, 328-338.	2.1	48
71	Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype. Journal of Alzheimer's Disease, 2016, 52, 359-371.	2.6	35
72	Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm. Free Radical Biology and Medicine, 2016, 91, 127-142.	2.9	98

#	Article	IF	Citations
73	Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins. Expert Review of Proteomics, 2016, 13, 259-274.	3.0	20
74	Novel role of 4-hydroxy-2-nonenal in AIFm2-mediated mitochondrial stress signaling. Free Radical Biology and Medicine, 2016, 91, 68-80.	2.9	41
75	Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. Free Radical Biology and Medicine, 2016, 91, 1-9.	2.9	74
76	Redox Proteomics in Human Biofluids: Sample Preparation, Separation and Immunochemical Tagging for Analysis of Protein Oxidation. Methods in Molecular Biology, 2016, 1303, 391-403.	0.9	7
77	Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage. Current Alzheimer Research, 2016, 13, 112-122.	1.4	15
78	Quantitative Phosphoproteomic Analyses of the Inferior Parietal Lobule from Three Different Pathological Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 49, 45-62.	2.6	33
79	Metabolic clues to salubrious longevity in the brain of the longestâ€lived rodent: the naked moleâ€rat. Journal of Neurochemistry, 2015, 134, 538-550.	3.9	15
80	Basal brain oxidative and nitrative stress levels are finely regulated by the interplay between superoxide dismutase 2 and p53. Journal of Neuroscience Research, 2015, 93, 1728-1739.	2.9	18
81	Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna—A Randomized, Cross-Over Clinical Study. PLoS ONE, 2015, 10, e0124988.	2.5	33
82	Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel?. Neurobiology of Disease, 2015, 84, 69-77.	4.4	26
83	Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with preâ€clinical AD, amnestic mild cognitive impairment and lateâ€stage AD. Journal of Neurochemistry, 2015, 133, 739-749.	3.9	276
84	Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease. Journal of Neurochemistry, 2015, 133, 750-765.	3.9	54
85	Bach1 Overexpression in Down Syndrome Correlates with the Alteration of the HO-1/BVR-A System: Insights for Transition to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1107-1120.	2.6	53
86	Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiology of Disease, 2015, 76, 13-23.	4.4	91
87	Superoxide induces protein oxidation in plasma and TNF-α elevation in macrophage culture: Insights into mechanisms of neurotoxicity following doxorubicin chemotherapy. Cancer Letters, 2015, 367, 157-161.	7.2	40
88	Age-related changes in the proteostasis network in the brain of the naked mole-rat: Implications promoting healthy longevity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2213-2224.	3.8	47
89	Oxidative stress in Alzheimer disease and mild cognitive impairment: evidence from human data provided by redox proteomics. Archives of Toxicology, 2015, 89, 1669-1680.	4.2	155
90	Vitamin D deficiency and Alzheimer disease: Common links. Neurobiology of Disease, 2015, 84, 84-98.	4.4	48

#	Article	IF	Citations
91	Redox signaling in neurodegeneration. Neurobiology of Disease, 2015, 84, 1-3.	4.4	4
92	mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiology of Disease, 2015, 84, 39-49.	4.4	261
93	Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants. Expert Review of Neurotherapeutics, 2015, 15, 19-40.	2.8	87
94	Oxidative Stress and Proteostasis Network: Culprit and Casualty of Alzheimer's-Like Neurodegeneration. Advances in Geriatrics, 2014, 2014, 1-14.	1.6	36
95	Rat hippocampal responses up to 90 days after a single nanoceria dose extends a hierarchical oxidative stress model for nanoparticle toxicity. Nanotoxicology, 2014, 8, 155-166.	3.0	26
96	Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radical Biology and Medicine, 2014, 71, 270-280.	2.9	87
97	Abeta, oxidative stress in Alzheimer disease: Evidence based on proteomics studies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1248-1257.	3.8	158
98	Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radical Biology and Medicine, 2014, 67, 387-395.	2.9	111
99	Statins more than cholesterol lowering agents in Alzheimer disease: Their pleiotropic functions as potential therapeutic targets. Biochemical Pharmacology, 2014, 88, 605-616.	4.4	73
100	Persistent Hepatic Structural Alterations Following Nanoceria Vascular Infusion in the Rat. Toxicologic Pathology, 2014, 42, 984-996.	1.8	26
101	Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochemical Journal, 2014, 463, 177-189.	3.7	93
102	The 2013 SFRBM discovery award: Selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. Free Radical Biology and Medicine, 2014, 74, 157-174.	2.9	103
103	Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1693-1706.	3.8	286
104	An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radical Biology and Medicine, 2014, 76, 89-95.	2.9	23
105	Redox proteomics: from protein modifications to cellular dysfunction and disease. Mass Spectrometry Reviews, 2014, 33, 1-6.	5.4	57
106	Redox proteomics and the dynamic molecular landscape of the aging brain. Ageing Research Reviews, 2014, 13, 75-89.	10.9	56
107	Inâ€Vivo Processing of Ceria Nanoparticles inside Liver: Impact on Freeâ€Radical Scavenging Activity and Oxidative Stress. ChemPlusChem, 2014, 79, 1083-1088.	2.8	65
108	Mass spectrometry and redox proteomics: Applications in disease. Mass Spectrometry Reviews, 2014, 33, 277-301.	5.4	98

#	Article	IF	CITATIONS
109	Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1333-1339.	3.8	53
110	Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1144-1153.	3.8	127
111	The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: It's time for reconciliation. Neurobiology of Disease, 2014, 62, 144-159.	4.4	109
112	O4-05-05: OXIDATIVE STRESS IN BRAIN AND LYMPHOCYTE MITOCHONDRIA IN ALZHEIMER'S DISEASE AND AMNESTIC MILD COGNITIVE IMPAIRMENT: TOWARD IDENTIFICATION OF PERIPHERAL BIOMARKERS IN THE PROGRESSION OF THIS DEMENTING DISORDER. , 2014, 10, P260-P260.		0
113	Abeta, oxidative stress in Alzheimer disease: Evidence based on proteomics studies. , 2014, 1842, 1248-1248.		1
114	Potential Therapeutic Effects of Statins in Alzheimer's Disease. , 2014, , 2339-2354.		0
115	Down Syndrome as a Special Case of Oxidatively Induced Developmental Dysregulation. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 127-142.	0.4	0
116	Amyloid $\langle i \rangle \hat{l}^2 \langle i \rangle$ -Peptide ($1 \hat{a} \in 42$)-Induced Oxidative Stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression. Antioxidants and Redox Signaling, 2013, 19, 823-835.	5.4	439
117	Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: Redox proteomics analysis of human brain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1249-1259.	3.8	109
118	Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biology, 2013, 1, 80-85.	9.0	108
119	Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease. Free Radical Biology and Medicine, 2013, 65, 595-606.	2.9	56
120	Lipid peroxidation triggers neurodegeneration: A redox proteomics view into the Alzheimer disease brain. Free Radical Biology and Medicine, 2013, 62, 157-169.	2.9	365
121	Apolipoprotein <scp>A</scp> â€ <scp>I</scp> : Insights from redox proteomics for its role in neurodegeneration. Proteomics - Clinical Applications, 2013, 7, 109-122.	1.6	59
122	Dietary vitamin D deficiency in rats from middle to old age leads to elevated tyrosine nitration and proteomics changes in levels of key proteins in brain: Implications for low vitamin D-dependent age-related cognitive decline. Free Radical Biology and Medicine, 2013, 65, 324-334.	2.9	66
123	Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: A proteomics study. Free Radical Biology and Medicine, 2013, 65, 1-14.	2.9	38
124	Brain Oxidative Stress in the Pathogenesis and Progression of Alzheimer's Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2013, , 99-118.	0.4	1
125	Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia. Current Gerontology and Geriatrics Research, 2012, 2012, 1-10.	1.6	139
126	Do Proteomics Analyses Provide Insights into Reduced Oxidative Stress in the Brain of an Alzheimer Disease Transgenic Mouse Model with an M631L Amyloid Precursor Protein Substitution and Thereby the Importance of Amyloid-Beta-Resident Methionine 35 in Alzheimer Disease Pathogenesis?. Antioxidants and Redox Signaling, 2012, 17, 1507-1514.	5.4	22

#	Article	IF	CITATIONS
127	4-Hydroxy-2-Nonenal, a Reactive Product of Lipid Peroxidation, and Neurodegenerative Diseases: A Toxic Combination Illuminated by Redox Proteomics Studies. Antioxidants and Redox Signaling, 2012, 17, 1590-1609.	5.4	184
128	HO-1/BVR-A System Analysis in Plasma from Probable Alzheimer's Disease and Mild Cognitive Impairment Subjects: A Potential Biochemical Marker for the Prediction of the Disease. Journal of Alzheimer's Disease, 2012, 32, 277-289.	2.6	43
129	Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. International Journal of Neuropsychopharmacology, 2012, 15, 981-987.	2.1	63
130	Rat brain pro-oxidant effects of peripherally administered 5nm ceria 30 days after exposure. NeuroToxicology, 2012, 33, 1147-1155.	3.0	44
131	Lack of p53 Decreases Basal Oxidative Stress Levels in the Brain Through Upregulation of Thioredoxin-1, Biliverdin Reductase-A, Manganese Superoxide Dismutase, and Nuclear Factor Kappa-B. Antioxidants and Redox Signaling, 2012, 16, 1407-1420.	5.4	30
132	Distribution, Elimination, and Biopersistence to 90 Days of a Systemically Introduced 30 nm Ceria-Engineered Nanomaterial in Rats. Toxicological Sciences, 2012, 127, 256-268.	3.1	114
133	Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 130-138.	3.8	103
134	Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 625-630.	3.8	267
135	Short-term molecular-level effects of silver nanoparticle exposure on the earthworm, Eisenia fetida. Environmental Pollution, 2012, 171, 249-255.	7.5	89
136	Lipopolysaccharide impairs amyloid beta efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood–brain barrier. Journal of Neuroinflammation, 2012, 9, 150.	7.2	102
137	Sex differences in brain proteomes of neuronâ€specific STAT3â€null mice after cerebral ischemia/reperfusion. Journal of Neurochemistry, 2012, 121, 680-692.	3.9	29
138	Redox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications. Antioxidants and Redox Signaling, 2012, 17, 1610-1655.	5.4	152
139	Redox Proteomics. Antioxidants and Redox Signaling, 2012, 17, 1487-1489.	5.4	62
140	Redox Proteomics Analyses of the Influence of Co-Expression of Wild-Type or Mutated LRRK2 and Tau on C. elegans Protein Expression and Oxidative Modification: Relevance to Parkinson Disease. Antioxidants and Redox Signaling, 2012, 17, 1490-1506.	5.4	43
141	Cell Cycle Proteins in Brain in Mild Cognitive Impairment: Insights into Progression to Alzheimer Disease. Neurotoxicity Research, 2012, 22, 220-230.	2.7	49
142	Oxidative Modification of Brain Proteins in Alzheimer's Disease: Perspective on Future Studies Based on Results of Redox Proteomics Studies. Journal of Alzheimer's Disease, 2012, 33, S243-S251.	2.6	57
143	Global Effects of Adriamycin Treatment on Mouse Splenic Protein Levels. Journal of Proteome Research, 2012, 11, 1054-1064.	3.7	5
144	Conformational Altered p53 as an Early Marker of Oxidative Stress in Alzheimer's Disease. PLoS ONE, 2012, 7, e29789.	2.5	59

#	Article	IF	CITATIONS
145	Oxidative Stress in HPV-Driven Viral Carcinogenesis: Redox Proteomics Analysis of HPV-16 Dysplastic and Neoplastic Tissues. PLoS ONE, 2012, 7, e34366.	2.5	63
146	Lack of p53 Affects the Expression of Several Brain Mitochondrial Proteins: Insights from Proteomics into Important Pathways Regulated by p53. PLoS ONE, 2012, 7, e49846.	2.5	14
147	Biliverdin reductaseâ€A: a novel drug target for atorvastatin in a dog preâ€clinical model of Alzheimer disease. Journal of Neurochemistry, 2012, 120, 135-146.	3.9	63
148	Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radical Biology and Medicine, 2012, 52, 2292-2301.	2.9	108
149	Alteration of hepatic structure and oxidative stress induced by intravenous nanoceria. Toxicology and Applied Pharmacology, 2012, 260, 173-182.	2.8	78
150	Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free Radical Research, 2011, 45, 59-72.	3.3	111
151	The identification of protein biomarkers for oxidative stress in Down syndrome. Expert Review of Proteomics, 2011, 8, 427-429.	3.0	26
152	Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action. Pharmacological Research, 2011, 63, 172-180.	7.1	86
153	Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacological Research, 2011, 64, 180-186.	7.1	67
154	Increased Protein and Lipid Oxidative Damage in Mitochondria Isolated from Lymphocytes from Patients with Alzheimer's Disease: Insights into the Role of Oxidative Stress in Alzheimer's Disease and Initial Investigations into a Potential Biomarker for this Dementing Disorder. Journal of Alzheimer's Disease, 2011, 24, 77-84.	2.6	100
155	Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opinion on Investigational Drugs, 2011, 20, 1243-1261.	4.1	44
156	Biliverdin reductase-A protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 480-487.	3.8	77
157	Circulating biomarkers of protein oxidation for Alzheimer disease: Expectations within limits. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 1785-1795.	2.3	56
158	Coenzyme Q10 and cognition in atorvastatin treated dogs. Neuroscience Letters, 2011, 501, 92-95.	2.1	15
159	Proteomic identification of specifically carbonylated brain proteins in APPNLh/APPNLh×PS-1P264L/PS-1P264L human double mutant knock-in mice model of Alzheimer disease as a function of age. Journal of Proteomics, 2011, 74, 2430-2440.	2.4	36
160	Atorvastatin and Aβ(1–40): Not as Simple as Cholesterol Reduction in Brain and Relevance to Alzheimer Disease. Experimental Neurology, 2011, 228, 15-18.	4.1	9
161	Redox Proteomics Analysis of Brains from Subjects with Amnestic Mild Cognitive Impairment Compared to Brains from Subjects with Preclinical Alzheimer's Disease: Insights into Memory Loss in MCI. Journal of Alzheimer's Disease, 2011, 23, 257-269.	2.6	85
162	Methionine-35 of A <i>\hat{l}^2</i> (1â \in "42): Importance for Oxidative Stress in Alzheimer Disease. Journal of Amino Acids, 2011, 2011, 1-10.	5.8	83

#	Article	lF	Citations
163	Identification of the oxidative stress proteome in the brain. Free Radical Biology and Medicine, 2011, 50, 487-494.	2.9	31
164	2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF- $\hat{l}\pm$ release: Implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radical Biology and Medicine, 2011, 50, 1630-1638.	2.9	135
165	Oxidative Stress in Alzheimer Disease: Synergy Between the Butterfield and Markesbery Laboratories. NeuroMolecular Medicine, 2011, 13, 19-22.	3.4	13
166	Preface for the Special Issue of Neuromolecular Medicine in Memory of the Life and Legacy of William R. Markesbery, M.D NeuroMolecular Medicine, 2011, 13, 1-2.	3.4	1
167	Lectinâ€affinity chromatography brain glycoproteomics and Alzheimer disease: Insights into protein alterations consistent with the pathology and progression of this dementing disorder. Proteomics - Clinical Applications, 2011, 5, 50-56.	1.6	36
168	Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid. Proteomics - Clinical Applications, 2011, 5, 167-178.	1.6	86
169	Proteomic analysis of brain proteins in APP/PSâ€1 human double mutant knockâ€in mice with increasing amyloid βâ€peptide deposition: Insights into the effects of in vivo treatment with <i>N</i> à€acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease. Proteomics, 2011, 11, 4243-4256.	2.2	39
170	Tuning of the proâ€oxidant and antioxidant activity of trolox through the controlled release from biodegradable poly(trolox ester) polymers. Journal of Biomedical Materials Research - Part A, 2011, 99A, 184-191.	4.0	26
171	Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects. Journal of Proteomics, 2011, 74, 1091-1103.	2.4	86
172	Oxidative and Nitrosative Modifications of Biliverdin Reductase-A in the Brain of Subjects with Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2011, 25, 623-633.	2.6	85
173	Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge. CNS and Neurological Disorders - Drug Targets, 2011, 10, 766-776.	1.4	15
174	Brain Protein Oxidation and Modification for Good or for Bad in Alzheimer's Disease. Advances in Neurobiology, 2011, , 585-605.	1.8	1
175	Spontaneous Vertebrate Models of Alzheimer Dementia: Selectively Bred Strains (SAM Strains). Neuromethods, 2011, , 271-293.	0.3	O
176	Decreased levels of PSD95 and two associated proteins and increased levels of BCl ₂ and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Aβ, and neurodegeneration in a prodromal stage of Alzheimer's disease. Journal of Neuroscience Research, 2010, 88, 469-477.	2.9	135
177	Role of Oxidative Stress in the Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 341-353.	2.6	282
178	Protein Carbonylation. Antioxidants and Redox Signaling, 2010, 12, 323-325.	5.4	311
179	Wild type but not mutant APP is involved in protective adaptive responses against oxidants. Amino Acids, 2010, 39, 271-283.	2.7	11
180	Age-related loss of phospholipid asymmetry in APP /APP x PS-1 /PS-1 human double mutant knock-in mice: Relevance to Alzheimer disease. Neurobiology of Disease, 2010, 38, 104-115.	4.4	37

#	Article	IF	Citations
181	Preclinical Alzheimer disease: Brain oxidative stress, \hat{Al}^2 peptide and proteomics. Neurobiology of Disease, 2010, 39, 221-228.	4.4	76
182	Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: An investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Research, 2010, 1333, 72-81.	2.2	94
183	Involvement of stat3 in mouse brain development and sexual dimorphism: A proteomics approach. Brain Research, 2010, 1362, 1-12.	2.2	21
184	In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid \hat{l}^2 -peptide of APP. Free Radical Biology and Medicine, 2010, 48, 136-144.	2.9	157
185	Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: Implications for ${\rm Al}^2$ accumulation in AD brain. Free Radical Biology and Medicine, 2010, 49, 1798-1803.	2.9	115
186	Potential in vivo amelioration by Nâ€acetylâ€Lâ€cysteine of oxidative stress in brain in human double mutant APP/PSâ€1 knockâ€in mice: Toward therapeutic modulation of mild cognitive impairment. Journal of Neuroscience Research, 2010, 88, 2618-2629.	2.9	63
187	The wheat germ agglutininâ€fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progression. Journal of Neuroscience Research, 2010, 88, 3566-3577.	2.9	34
188	William R. Markesbery, M.D.: A Legacy of Excellence in Alzheimer's Disease Research and a Life Well-Lived. Journal of Alzheimer's Disease, 2010, 20, 3-4.	2.6	82
189	Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17385-17390.	7.1	129
190	Redox Proteomic Analysis of Carbonylated Brain Proteins in Mild Cognitive Impairment and Early Alzheimer's Disease. Antioxidants and Redox Signaling, 2010, 12, 327-336.	5.4	108
191	Brain Distribution and Toxicological Evaluation of a Systemically Delivered Engineered Nanoscale Ceria. Toxicological Sciences, 2010, 116, 562-576.	3.1	95
192	Oxidatively Modified Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) and Alzheimer's Disease: Many Pathways to Neurodegeneration. Journal of Alzheimer's Disease, 2010, 20, 369-393.	2.6	252
193	Doxorubicin-Induced Thymus Senescence. Journal of Proteome Research, 2010, 9, 6232-6241.	3.7	25
194	Measurement of Oxidized/Reduced Glutathione Ratio. Methods in Molecular Biology, 2010, 648, 269-277.	0.9	260
195	Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's diseaseâ^†. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 924-929.	2.4	249
196	Redox Homeostasis and Cellular Stress Response in Aging and Neurodegeneration. Methods in Molecular Biology, 2010, 610, 285-308.	0.9	129
197	Chemo Brain (Chemo Fog) as a Potential Side Effect of Doxorubicin Administration: Role of Cytokine-Induced, Oxidative/Nitrosative Stress in Cognitive Dysfunction. Advances in Experimental Medicine and Biology, 2010, 678, 147-156.	1.6	83
198	Biodistribution and oxidative stress effects of a systemically-introduced commercial ceria engineered nanomaterial. Nanotoxicology, 2009, 3, 234-248.	3.0	92

#	Article	IF	CITATIONS
199	Mrp1 Localization and Function in Cardiac Mitochondria after Doxorubicin. Molecular Pharmacology, 2009, 75, 1117-1126.	2.3	43
200	Proteomics analysis of protein expression and specific protein oxidation in human papillomavirus transformed keratinocytes upon UVB irradiation. Journal of Cellular and Molecular Medicine, 2009, 13, 1809-1822.	3.6	23
201	Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. Journal of Cellular and Molecular Medicine, 2009, 13, 2019-2029.	3.6	111
202	Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Research, 2009, 1274, 66-76.	2.2	182
203	Proteomic identification of nitrated brain proteins in traumatic brainâ€injured rats treated postinjury with gammaâ€glutamylcysteine ethyl ester: Insights into the role of elevation of glutathione as a potential therapeutic strategy for traumatic brain injury. Journal of Neuroscience Research, 2009, 87, 408-417.	2.9	53
204	Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathologica, 2009, 118, 131-150.	7.7	194
205	Glutathionylation of the Pro-apoptotic Protein p53 in Alzheimer's Disease Brain: Implications for AD Pathogenesis. Neurochemical Research, 2009, 34, 727-733.	3.3	72
206	Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. Journal of Bioenergetics and Biomembranes, 2009, 41, 441-446.	2.3	103
207	Redox proteomics identification of 4â€hydroxynonenalâ€modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics - Clinical Applications, 2009, 3, 682-693.	1.6	172
208	Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. Journal of Neurochemistry, 2009, 111, 915-933.	3.9	149
209	Protective effect of quercetin in primary neurons against Aβ(1–42): relevance to Alzheimer's disease. Journal of Nutritional Biochemistry, 2009, 20, 269-275.	4.2	359
210	Proteomics-Determined Differences in the Concanavalin-A-Fractionated Proteome of Hippocampus and Inferior Parietal Lobule in Subjects with Alzheimer's Disease and Mild Cognitive Impairment: Implications for Progression of AD. Journal of Proteome Research, 2009, 8, 471-482.	3.7	91
211	In vivo amelioration of adriamycin induced oxidative stress in plasma by gamma-glutamylcysteine ethyl ester (GCEE). Cancer Letters, 2009, 282, 25-29.	7.2	25
212	Lipopolysaccharide alters the blood–brain barrier transport of amyloid β protein: A mechanism for inflammation in the progression of Alzheimer's disease. Brain, Behavior, and Immunity, 2009, 23, 507-517.	4.1	218
213	Methylmalonateâ€induced seizures are attenuated in inducible nitric oxide synthase knockout mice. International Journal of Developmental Neuroscience, 2009, 27, 157-163.	1.6	14
214	Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Research Reviews, 2009, 8, 1-17.	10.9	73
215	Nitric Oxide in Cell Survival: A Janus Molecule. Antioxidants and Redox Signaling, 2009, 11, 2717-2739.	5.4	184
216	Heme Oxygenase as a Therapeutic Funnel in Nutritional Redox Homeostasis and Cellular Stress Response., 2009,, 39-52.		1

#	Article	IF	CITATIONS
217	Detection of 4-Hydroxy-2-Nonenal- and 3-Nitrotyrosine-Modified Proteins Using a Proteomics Approach. Methods in Molecular Biology, 2009, 519, 351-361.	0.9	15
218	Proteomics Identification of Carbonylated and HNE-Bound Brain Proteins in Alzheimer's Disease. Methods in Molecular Biology, 2009, 566, 123-135.	0.9	28
219	Nitrated Proteins in the Progression of Alzheimer's Disease: A Proteomics Comparison of Mild Cognitive Impairment and Alzheimer's Disease Brain. , 2009, , 137-157.		1
220	Proteomics Identification of Oxidatively Modified Proteins in Bra. Methods in Molecular Biology, 2009, 564, 291-301.	0.9	6
221	Protein Levels and Activity of Some Antioxidant Enzymes in Hippocampus of Subjects with Amnestic Mild Cognitive Impairment. Neurochemical Research, 2008, 33, 2540-2546.	3.3	100
222	Redox proteomics studies of <i>in vivo</i> amyloid betaâ€peptide animal models of Alzheimer's disease: Insight into the role of oxidative stress. Proteomics - Clinical Applications, 2008, 2, 685-696.	1.6	21
223	Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease. Free Radical Biology and Medicine, 2008, 45, 81-85.	2.9	62
224	Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radical Biology and Medicine, 2008, 45, 1420-1425.	2.9	74
225	Proteomic analysis of brain protein expression levels in NF-κβ p50 â°'/â^' homozygous knockout mice. Brain Research, 2008, 1240, 22-30.	2.2	7
226	Elevated levels of proâ€apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE,in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2008, 12, 987-994.	3.6	98
227	Unconjugated bilirubin differentially affects the redox status of neuronal and astroglial cells. Neurobiology of Disease, 2008, 29, 30-40.	4.4	57
228	Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiology of Disease, 2008, 29, 456-464.	4.4	97
229	Redox proteomic identification of 4-Hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiology of Disease, 2008, 30, 107-120.	4.4	236
230	Bilirubin injury to neurons: Contribution of oxidative stress and rescue by glycoursodeoxycholic acid. NeuroToxicology, 2008, 29, 259-269.	3.0	89
231	Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer's disease. Neurobiology of Aging, 2008, 29, 51-70.	3.1	179
232	Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 549-558.	3.8	72
233	Alterations of some membrane transport proteins in Alzheimer's disease: role of amyloid \hat{l}^2 -peptide. Molecular BioSystems, 2008, 4, 36-41.	2.9	25
234	Redox proteomics: understanding oxidative stress in the progression of age-related neurodegenerative disorders. Expert Review of Proteomics, 2008, 5, 157-160.	3.0	49

#	Article	IF	CITATIONS
235	Identification of 3â€Nitrotyosineâ€Modified Brain Proteins by Redox Proteomics. Methods in Enzymology, 2008, 440, 295-308.	1.0	22
236	Obesity and Hypertriglyceridemia Produce Cognitive Impairment. Endocrinology, 2008, 149, 2628-2636.	2.8	332
237	Slotâ€Blot Analysis of 3â€Nitrotyrosineâ€Modified Brain Proteins. Methods in Enzymology, 2008, 440, 309-316.	1.0	23
238	An Overview of Biofunctional Membranes for Tunable Separations, Metal-Ion Capture, and Enzyme Catalysis Based on Research from the Laboratories of Allan Butterfield and Dibakar Bhattacharyya. Separation Science and Technology, 2008, 43, 3942-3954.	2.5	2
239	Detection of Carbonylated Proteins in 2-D SDS Page Separations. Methods in Molecular Biology, 2008, 476, 149-159.	0.9	11
240	Redox Proteomics Identification of Oxidatively Modified Proteins in Alzheimer's Disease Brain and in Brain from a Rodent Model of Familial Parkinson's Disease: Insights into Potential Mechanisms of Neurodegeneration. , 2008, , 149-167.		1
241	Nitric Oxide and Cellular Stress Response in Brain Aging and Neurodegenerative Disorders. , 2007, , 115-134.		4
242	Proteomics Analysis of the Alzheimer's Disease Hippocampal Proteome. Journal of Alzheimer's Disease, 2007, 11, 153-164.	2.6	222
243	Redox Proteomics Identification of Oxidatively Modified Brain Proteins in Alzheimer's Disease and Mild Cognitive Impairment: Insights into the Progression of this Dementing Disorder. Journal of Alzheimer's Disease, 2007, 12, 61-72.	2.6	121
244	Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)—2′,3′-dideoxycytidine (ddC): Relevance to HIV-dementia. Experimental Neurology, 2007, 204, 29-20-20-20-20-20-20-20-20-20-20-20-20-20-	38. ^{4.1}	51
245	Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nature Reviews Neuroscience, 2007, 8, 766-775.	10.2	1,208
246	Natural antioxidants in Alzheimer's disease. Expert Opinion on Investigational Drugs, 2007, 16, 1921-1931.	4.1	136
247	Amyloid β-Peptide(1-42), Oxidative Stress, and Alzheimer's Disease. , 2007, , 83-92.		2
248	Proteomic Identification of Oxidized Mitochondrial Proteins following Experimental Traumatic Brain Injury. Journal of Neurotrauma, 2007, 24, 772-789.	3.4	141
249	Oxidative stress in the aging murine olfactory bulb: Redox proteomics and cellular localization. Journal of Neuroscience Research, 2007, 85, 373-385.	2.9	38
250	Glutathione elevation by \hat{l}^3 -glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. Journal of Neuroscience Research, 2007, 85, 497-503.	2.9	120
251	An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. Journal of Neuroscience Research, 2007, 85, 1506-1514.	2.9	155
252	Difluoromethylornithine Decreases Long-Lasting Protein Oxidation Induced by Neonatal Ethanol Exposure in the Hippocampus of Adolescent Rats. Alcoholism: Clinical and Experimental Research, 2007, 31, 887-894.	2.4	6

#	Article	IF	Citations
253	Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. Journal of Neurochemistry, 2007, 100, 191-201.	3.9	159
254	In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. Journal of Neurochemistry, 2007, 101, 709-717.	3.9	56
255	Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimer's disease. Brain Research, 2007, 1148, 243-248.	2.2	211
256	Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and α-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: Implications for Alzheimer's disease. Free Radical Biology and Medicine, 2007, 42, 371-384.	2.9	125
257	Roles of amyloid \hat{l}^2 -peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radical Biology and Medicine, 2007, 43, 658-677.	2.9	493
258	Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. Journal of Cellular and Molecular Medicine, 2007, 11, 839-851.	3.6	83
259	Regional Expression of Key Cell Cycle Proteins in Brain from Subjects with Amnestic Mild Cognitive Impairment. Neurochemical Research, 2007, 32, 655-662.	3.3	43
260	Redox Regulation of Cellular Stress Response in Aging and Neurodegenerative Disorders: Role of Vitagenes. Neurochemical Research, 2007, 32, 757-773.	3.3	219
261	Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2007, 7, 147-156.	3.4	315
262	Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Frontiers in Bioscience - Landmark, 2007, 12, 1107.	3.0	274
263	Redox Regulation of Heat Shock Protein Expression by Signaling Involving Nitric Oxide and Carbon Monoxide: Relevance to Brain Aging, Neurodegenerative Disorders, and Longevity. Antioxidants and Redox Signaling, 2006, 8, 444-477.	5.4	112
264	Oxidative Stress and Therapeutic Approaches in HIV Dementia. Antioxidants and Redox Signaling, 2006, 8, 2089-2100.	5.4	71
265	Proteomics Analyses of Specific Protein Oxidation and Protein Expression in Aged Rat Brain and Its Modulation by L-Acetylcarnitine: Insights Into the Mechanisms of Action of This Proposed Therapeutic Agent for CNS Disorders Associated with Oxidative Stress. Antioxidants and Redox Signaling, 2006, 8, 381-394.	5.4	96
266	Protein Oxidation and Lipid Peroxidation in Brain of Subjects with Alzheimer's Disease: Insights into Mechanism of Neurodegeneration from Redox Proteomics. Antioxidants and Redox Signaling, 2006, 8, 2021-2037.	5.4	224
267	Oxidative Stress in Neurodegenerative Disorders. Antioxidants and Redox Signaling, 2006, 8, 1971-1973.	5.4	69
268	In vivo protection of synaptosomes by ferulic acid ethyl ester (FAEE) from oxidative stress mediated by 2,2-azobis(2-amidino-propane)dihydrochloride (AAPH) or Fe2+/H2O2: Insight into mechanisms of neuroprotection and relevance to oxidative stress-related neurodegenerative disorders. Neurochemistry International, 2006, 48, 318-327.	3.8	114
269	Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neuroscience Letters, 2006, 397, 170-173.	2.1	227
270	In vitro and in vivo neuroprotection by \hat{I}^3 -glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson's disease. Neuroscience Letters, 2006, 402, 137-141.	2.1	40

#	Article	IF	CITATIONS
271	Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiology of Aging, 2006, 27, 918-925.	3.1	222
272	Quantitative proteomics analysis of differential protein expression and oxidative modification of specific proteins in the brains of old mice. Neurobiology of Aging, 2006, 27, 1010-1019.	3.1	129
273	Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: Mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. Neurobiology of Aging, 2006, 27, 1020-1034.	3.1	119
274	Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Aβ(1–42): Implications for Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1239-1249.	3.1	89
275	Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD. Neurobiology of Aging, 2006, 27, 1564-1576.	3.1	296
276	Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: An initial assessment. Journal of Alzheimer's Disease, 2006, 10, 391-397.	2.6	107
277	Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid β-peptide (1-42), H2O2 and kainic acid: implications for A. Journal of Neurochemistry, 2006, 96, 1322-1335.	3.9	109
278	REVIEW: Pin1 in Alzheimer's disease. Journal of Neurochemistry, 2006, 98, 1697-1706.	3.9	156
279	Redox proteomics in some age-related neurodegenerative disorders or models thereof. NeuroRx, 2006, 3, 344-357.	6.0	36
280	Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. Journal of Nutritional Biochemistry, 2006, 17, 73-88.	4.2	115
281	Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Aβ(1â€⁴42)â⁻†. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 833, 3-11.	2.3	67
282	Identification of AGE-modified proteins in SH-SY5Y and OLN-93 Cells. Neurotoxicity Research, 2006, 9, 255-268.	2.7	9
283	Redox proteomic identification of oxidized cardiac proteins in Adriamycin-treated mice. Free Radical Biology and Medicine, 2006, 41, 1470-1477.	2.9	57
284	In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: Relevance to Alzheimer's disease and other oxidative stress-related neurodegenerative disorders. Free Radical Biology and Medicine, 2006, 41, 1694-1703.	2.9	87
285	Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics. European Journal of Pharmacology, 2006, 545, 39-50.	3.5	316
286	Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Aβ(1–42) toxicity. Brain Research, 2006, 1069, 198-206.	2.2	41
287	Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiology of Disease, 2006, 22, 76-87.	4.4	335
288	Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer's disease. Neurobiology of Disease, 2006, 22, 223-232.	4.4	356

#	Article	IF	CITATIONS
289	Adriamycin-induced, TNF-α-mediated central nervous system toxicity. Neurobiology of Disease, 2006, 23, 127-139.	4.4	204
290	Protective effect of D609 against amyloid-beta 1–42-induced oxidative modification of neuronal proteins: Redox proteomics study. Journal of Neuroscience Research, 2006, 84, 409-417.	2.9	54
291	Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1–42-mediated oxidative stress and neurotoxicity: Implications for Alzheimer's disease. Journal of Neuroscience Research, 2006, 84, 398-408.	2.9	135
292	In vivo protective effects of ferulic acid ethyl ester against amyloid-beta peptide 1–42-induced oxidative stress. Journal of Neuroscience Research, 2006, 84, 418-426.	2.9	119
293	Chemical Modification of Proteins by Reactive Oxygen Species. , 2006, , 1-23.		15
294	ICAT (Isotope-Coded Affinity Tag) Approach to Redox Proteomics: Identification and Quantification of Oxidant-Sensitive Protein Thiols., 2006,, 267-285.		2
295	Quantitative Determination of Free and Protein-Associated 3-Nitrotyrosine and S-Nitrosothiols in the Circulation by Mass Spectrometry and Other Methodologies: A Critical Review and Discussion from the Analytical and Review Point of View., 2006,, 287-341.		3
296	The Covalent Advantage: A New Paradigm for Cell Signaling Mediated by Thiol Reactive Lipid Oxidation Products., 2006,, 343-367.		4
297	Early Molecular Events during Response to Oxidative Stress in Human Cells by Differential Proteomics., 2006,, 369-397.		3
298	Oxidative Damage to Proteins: Structural Modifications and Consequences in Cell Function. , 2006, , 399-471.		18
299	Oxidative Damage and Cellular Senescence: Lessons from Bacteria and Yeast. , 2006, , 473-484.		1
300	Proteins as Sensitive Biomarkers of Human Conditions Associated with Oxidative Stress. , 2006, , 485-525.		3
301	Degradation and Accumulation of Oxidized Proteins in Age-Related Diseases. , 2006, , 527-562.		6
302	Oxidized Proteins in Cardiac Ischemia and Reperfusion., 2006,, 605-649.		2
303	The Chemistry of Protein Modifications Elicited by Nitric Oxide and Related Nitrogen Oxides. , 2006, , 25-58.		4
304	Proteome Analysis of Oxidative Stress: Glutathionyl Hemoglobin in Diabetic and Uremic Patients. , 2006, , 651-667.		3
305	Glyco-oxidative Biochemistry in Diabetic Renal Injury. , 2006, , 669-680.		О
306	Quantitative Screening of Protein Glycation, Oxidation, and Nitration Adducts by LC-MS/MS: Protein Damage in Diabetes, Uremia, Cirrhosis, and Alzheimer's Disease., 2006,, 681-727.		16

#	Article	IF	Citations
307	Protein Targets and Functional Consequences of Tyrosine Nitration in Vascular Disease. , 2006, , 729-786.		1
308	Oxidation of Artery Wall Proteins by Myeloperoxidase: A Proteomics Approach., 2006,, 787-811.		0
309	Oxidative Stress and Protein Oxidation in Pre-Eclampsia. , 2006, , 813-829.		0
310	Involvement of Oxidants in the Etiology of Chronic Airway Diseases: Proteomic Approaches to Identify Redox Processes in Epithelial Cell Signaling and Inflammation. , 2006, , 831-876.		0
311	Sequestering Agents of Intermediate Reactive Aldehydes as Inhibitors of Advanced Lipoxidation End-Products (ALEs)., 2006,, 877-929.		1
312	Mass Spectrometry Approaches for the Molecular Characterization of Oxidatively/Nitrosatively Modified Proteins., 2006,, 59-99.		8
313	Thiol-Disulfide Oxidoreduction of Protein Cysteines: Old Methods Revisited for Proteomics. , 2006, , 101-122.		3
314	Carbonylated Proteins and Their Implication in Physiology and Pathology. , 2006, , 123-168.		11
315	S-Nitrosation of Cysteine Thiols as a Redox Signal. , 2006, , 169-188.		1
316	Detection of Glycated and Glyco-Oxidated Proteins. , 2006, , 189-232.		0
317	MudPIT (Multidimensional Protein Identification Technology) for Identification of Post-Translational Protein Modifications in Complex Biological Mixtures., 2006,, 233-252.		2
318	Use of a Proteomic Technique to Identify Oxidant-Sensitive Thiol Proteins in Cultured Cells., 2006,, 253-265.		4
319	Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Molecular Cancer Therapeutics, 2006, 5, 2851-2860.	4.1	40
320	Redox proteomics in some age-related neurodegenerative disorders or models thereof. Neurotherapeutics, 2006, 3, 344-357.	4.4	0
321	The critical role of methionine 35 in Alzheimer's amyloid β-peptide (1–42)-induced oxidative stress and neurotoxicity. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1703, 149-156.	2.3	228
322	Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. Journal of Neurochemistry, 2005, 92, 749-758.	3.9	255
323	Proteomic identification of differentially expressed proteins in the aging murine olfactory system and transcriptional analysis of the associated genes. Journal of Neurochemistry, 2005, 94, 380-392.	3.9	49
324	The senescence-accelerated prone mouse (SAMP8): A model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Experimental Gerontology, 2005, 40, 774-783.	2.8	297

#	Article	IF	Citations
325	Proteomic identification of proteins oxidized by $\hat{Al^2}(1\hat{a}\in 42)$ in synaptosomes: Implications for Alzheimer's disease. Brain Research, 2005, 1044, 206-215.	2.2	137
326	HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Research Reviews, 2005, 50, 14-26.	9.0	97
327	Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice-A model of familial amyotrophic lateral sclerosis. Free Radical Biology and Medicine, 2005, 38, 960-968.	2.9	141
328	In vivo protection of synaptosomes from oxidative stress mediated by Fe2+/H2O2 or 2,2-azobis-(2-amidinopropane) dihydrochloride by the glutathione mimetic tricyclodecan-9-yl-xanthogenate. Free Radical Biology and Medicine, 2005, 38, 1023-1031.	2.9	42
329	Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic miceâ€"a model of familial amyotrophic lateral sclerosis. Free Radical Biology and Medicine, 2005, 39, 453-462.	2.9	129
330	Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: Involvement of the transcription factor Nrf2. Journal of Neuroscience Research, 2005, 79, 509-521.	2.9	158
331	?-Glutamylcysteine ethyl ester protection of proteins from A?(1-42)-mediated oxidative stress in neuronal cell culture: A proteomics approach. Journal of Neuroscience Research, 2005, 79, 707-713.	2.9	46
332	?-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against A?(1-42)-mediated oxidative stress and neurotoxicity: Implications for Alzheimer's disease. Journal of Neuroscience Research, 2005, 79, 700-706.	2.9	62
333	Lentivirus Infection Causes Neuroinflammation and Neuronal Injury in Dorsal Root Ganglia: Pathogenic Effects of STAT-1 and Inducible Nitric Oxide Synthase. Journal of Immunology, 2005, 175, 1118-1126.	0.8	39
334	Proteomic Analysis of Protein Expression and Oxidative Modification in R6/2 Transgenic Mice. Molecular and Cellular Proteomics, 2005, 4, 1849-1861.	3.8	156
335	Proteomics analysis of human astrocytes expressing the HIV protein Tat. Molecular Brain Research, 2005, 133, 307-316.	2.3	42
336	Proteomic analysis of oxidatively modified proteins induced by the mitochondrial toxin 3-nitropropionic acid in human astrocytes expressing the HIV protein tat. Molecular Brain Research, 2005, 133, 299-306.	2.3	23
337	Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the $A\hat{l}^2$ region of amyloid precursor protein. Molecular Brain Research, 2005, 138, 8-16.	2.3	73
338	Mitochondrial associated metabolic proteins are selectively oxidized in A30P α-synuclein transgenic mice—a model of familial Parkinson's disease. Neurobiology of Disease, 2005, 18, 492-498.	4.4	157
339	Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochemistry International, 2005, 46, 159-168.	3.8	117
340	Protection against amyloid beta-peptide (1–42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: Implications for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 140-148.	3.8	69
341	Neurotoxicity and oxidative stress in D1M-substituted Alzheimer's $\hat{Al^2}(1-42)$: relevance to N-terminal methionine chemistry in small model peptides. Peptides, 2005, 26, 665-673.	2.4	16
342	Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. Journal of the Neurological Sciences, 2005, 233, 145-162.	0.6	361

#	Article	IF	CITATIONS
343	Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: Insight into chemobrain. Free Radical Research, 2005, 39, 1147-1154.	3.3	153
344	Proteomics Identification of Oxidatively Modified Proteins in the Alzheimer's Disease Brain and Models Thereof. Oxidative Stress and Disease, 2005, , 1-25.	0.3	О
345	Protective Effect of the Xanthate, D609, on Alzheimer's Amyloid β-peptide (1–42)-induced Oxidative Stress in Primary Neuronal Cells. Free Radical Research, 2004, 38, 449-458.	3.3	81
346	Human endogenous retrovirus glycoprotein–mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nature Neuroscience, 2004, 7, 1088-1095.	14.8	343
347	Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Research, 2004, 1000, 1-7.	2.2	199
348	Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Research, 2004, 1004, 193-197.	2.2	102
349	Antisense directed at the ${\rm A\hat{l}^2}$ region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Research, 2004, 1018, 86-96.	2.2	121
350	A link between hyperbilirubinemia, oxidative stress and injury to neocortical synaptosomes. Brain Research, 2004, 1026, 33-43.	2.2	86
351	Oxidatively Modified GST and MRP1 in Alzheimer?s Disease Brain: Implications for Accumulation of Reactive Lipid Peroxidation Products. Neurochemical Research, 2004, 29, 2215-2220.	3.3	148
352	Proteomic analysis of brain proteins in the gracile axonal dystrophy (<i>gad</i>) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxylâ€ŧerminal hydrolase Lâ€1, reveals oxidation of key proteins. Journal of Neurochemistry, 2004, 88, 1540-1546.	3.9	89
353	Effects of apolipoprotein E on the human immunodeficiency virus protein tat in neuronal cultures and synaptosomes. Journal of Neuroscience Research, 2004, 77, 532-539.	2.9	41
354	Ethyl Ferulate, a Lipophilic Polyphenol, Induces HO-1 and Protects Rat Neurons Against Oxidative Stress. Antioxidants and Redox Signaling, 2004, 6, 811-818.	5.4	151
355	Role of Phenylalanine 20 in Alzheimer's Amyloid \hat{l}^2 -Peptide (1-42)-Induced Oxidative Stress and Neurotoxicity. Chemical Research in Toxicology, 2004, 17, 1743-1749.	3.3	46
356	Free Radicals: Key to Brain Aging and Heme Oxygenase as a Cellular Response to Oxidative Stress. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2004, 59, M478-M493.	3.6	192
357	Redox Regulation in Neurodegeneration and Longevity: Role of the Heme Oxygenase and HSP70 Systems in Brain Stress Tolerance. Antioxidants and Redox Signaling, 2004, 6, 895-913.	5.4	95
358	Proteomics Analysis in Alzheimer's Disease: New Insights into Mechanisms of Neurodegeneration. International Review of Neurobiology, 2004, 61, 159-188.	2.0	21
359	Alzheimer's amyloid β-peptide (1–42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiology of Aging, 2004, 25, 563-568.	3.1	129
360	4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. Neuroscience Letters, 2004, 356, 155-158.	2.1	68

#	Article	IF	CITATIONS
361	APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease. Neuroscience Letters, 2004, 368, 148-150.	2.1	63
362	Free radicals and brain aging. Clinics in Geriatric Medicine, 2004, 20, 329-359.	2.6	252
363	Rodent Aβ(1–42) exhibits oxidative stress properties similar to those of human Aβ(1–42): Implications for proposed mechanisms of toxicity. Journal of Alzheimer's Disease, 2004, 6, 515-525.	2.6	80
364	Amyloid βâ€Peptide(1â€42) Contributes to the Oxidative Stress and Neurodegeneration Found in Alzheimer Disease Brain. Brain Pathology, 2004, 14, 426-432.	4.1	218
365	The Glutamatergic System in Alzheimer's Disease Brain: Dysfunction Associated with Amyloid β-Peptide and Oxidative Stress. , 2004, , 251-262.		2
366	Redox Regulation in Neurodegeneration and Longevity: Role of the Heme Oxygenase and HSP70 Systems in Brain Stress Tolerance. Antioxidants and Redox Signaling, 2004, 6, 895-913.	5.4	18
367	Acrolein inhibits NADH-linked mitochondrial enzyme activity: Implications for Alzheimer's disease. Neurotoxicity Research, 2003, 5, 515-519.	2.7	106
368	Antioxidant activity of X-34 in synaptosomal and neuronal systems. Brain Research, 2003, 988, 173-179.	2.2	7
369	Elevation of mitochondrial glutathione by ?-glutamylcysteine ethyl ester protects mitochondria against peroxynitrite-induced oxidative stress. Journal of Neuroscience Research, 2003, 74, 917-927.	2.9	105
370	The antioxidants αâ€lipoic acid and <i>N</i> à€acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. Journal of Neurochemistry, 2003, 84, 1173-1183.	3.9	415
371	Proteomic identification of nitrated proteins in Alzheimer's disease brain. Journal of Neurochemistry, 2003, 85, 1394-1401.	3.9	514
372	Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. Journal of Neurochemistry, 2003, 86, 1313-1327.	3.9	171
373	Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid β-peptide (1–42) in a transgenic Caenorhabditis elegans model. Neurobiology of Aging, 2003, 24, 415-420.	3.1	345
374	The Glutamatergic System and Alzheimer???s Disease. CNS Drugs, 2003, 17, 641-652.	5.9	220
375	Derivatives of Xanthic Acid are Novel Antioxidants: Application to Synaptosomes. Free Radical Research, 2003, 37, 355-365.	3.3	30
376	Intracellular Human Immunodeficiency Virus Tat Expression in Astrocytes Promotes Astrocyte Survival but Induces Potent Neurotoxicity at Distant Sites via Axonal Transport. Journal of Biological Chemistry, 2003, 278, 13512-13519.	3.4	160
377	Amyloid β-Peptide [1-42]-Associated Free Radical-Induced Oxidative Stress And Neurodegeneration in Alzheimers Disease Brain: Mechanisms and Consequences. Current Medicinal Chemistry, 2003, 10, 2651-2659.	2.4	151
378	Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease. Italian Journal of Biochemistry, 2003, 52, 177-81.	0.3	63

#	Article	IF	Citations
379	Vitamin E and Neurodegenerative Disorders Associated with Oxidative Stress. Nutritional Neuroscience, 2002, 5, 229-239.	3.1	136
380	Amyloid \hat{l}^2 -peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. Journal of Alzheimer's Disease, 2002, 4, 193-201.	2.6	155
381	Amyloid \hat{l}^2 -peptide (1-42)-induced Oxidative Stress and Neurotoxicity: Implications for Neurodegeneration in Alzheimer's Disease Brain. A Review. Free Radical Research, 2002, 36, 1307-1313.	3.3	694
382	Increased Protein Oxidation and Decreased Creatine Kinase BB Expression and Activity after Spinal Cord Contusion Injury. Journal of Neurotrauma, 2002, 19, 491-502.	3.4	77
383	Role of glycine-33 and methionine-35 in Alzheimer $\hat{a} \in \mathbb{N}$ s amyloid \hat{l}^2 -peptide $1\hat{a} \in \mathbb{N}$ 42-associated oxidative stress and neurotoxicity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1586, 190-198.	3.8	75
384	Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid β-peptide 1–42. Peptides, 2002, 23, 1299-1309.	2.4	140
385	Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death1. Neurobiology of Aging, 2002, 23, 655-664.	3.1	628
386	Apolipoprotein E modulates Alzheimer's Aβ(1–42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Research, 2002, 924, 90-97.	2.2	125
387	Lipid peroxidation and protein oxidation in Alzheimera€ ™s disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress 1,2 1Guest Editors: Mark A. Smith and George Perry 2This article is part of a series of reviews on "Causes and Consequences of Oxidative Stress in Alzheimer's Disease.―The full list of papers may be found on the	2.9	893
388	Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid β-peptide (1–42). Free Radical Biology and Medicine, 2002, 32, 1205-121	.1 ^{2.9}	87
389	Proteomic identification of oxidatively modified proteins in alzheimer's disease brain. part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radical Biology and Medicine, 2002, 33, 562-571.	2.9	545
390	Elevation of brain glutathione by ?-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. Journal of Neuroscience Research, 2002, 68, 776-784.	2.9	100
391	Elevated glutathione as a therapeutic strategy in Alzheimer's disease. Drug Development Research, 2002, 56, 428-437.	2.9	41
392	Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: structure-activity studies. Journal of Nutritional Biochemistry, 2002, 13, 273-281.	4.2	434
393	Amyloid \hat{I}^2 -Peptide Effects on Synaptosomes from Apolipoprotein E-Deficient Mice. Journal of Neurochemistry, 2002, 74, 1579-1586.	3.9	54
394	Oxidative Modification of Creatine Kinase BB in Alzheimer's Disease Brain. Journal of Neurochemistry, 2002, 74, 2520-2527.	3.9	242
395	Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinaseâ€related proteinâ€f2, αâ€enolase and heat shock cognateâ€f71. Journal of Neurochemistry 2002, 82, 1524-1532.	/ ,3 . 9	528
396	Oxidative stress in synaptosomal proteins from mutant presenilin-1 knock-in mice: implications for familial Alzheimer's disease. Neurochemical Research, 2002, 27, 417-421.	3.3	32

#	Article	IF	Citations
397	3-nitropropionic acid-induced changes in bilayer fluidity in synaptosomal membranes: implications for Huntington's disease. Neurochemical Research, 2002, 27, 507-511.	3.3	18
398	The hydrophobic environment of Met35 of Alzheimer's $\hat{Al^2}(1\hat{a} \in 42)$ is important for the neurotoxic and oxidative properties of the peptide. Neurotoxicity Research, 2002, 4, 219-223.	2.7	52
399	Different Mechanisms of Oxidative Stress and Neurotoxicity for Alzheimerâ€~s Aβ(1â^'42) and Aβ(25â^'35). Journal of the American Chemical Society, 2001, 123, 5625-5631.	13.7	325
400	Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochemistry International, 2001, 39, 141-149.	3.8	170
401	Vulnerability of Synaptosomes from ApoE Knock-Out Mice to Structural and Oxidative Modifications Induced by Al̂²(1âˆ٬40):  Implications for Alzheimer's Disease. Biochemistry, 2001, 40, 2548-2554.	2.5	66
402	Beneficial Effects of Dietary Restriction on Cerebral Cortical Synaptic Terminals. Journal of Neurochemistry, 2001, 75, 314-320.	3.9	111
403	The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of $\hat{Al^2}$ 1-42. Journal of Neurochemistry, 2001, 78, 413-416.	3.9	428
404	Role of spermine in amyloid ?-peptide-associated free radical-induced neurotoxicity. Journal of Neuroscience Research, 2001, 63, 395-401.	2.9	78
405	5-Aminosalicylic acid protection against oxidative damage to synaptosomal membranes by alkoxyl radicals in vitro. Neurochemical Research, 2001, 26, 23-29.	3.3	16
406	Vitamin E Prevents Alzheimer's Amyloid ß-Peptide (1-42)-Induced Neuronal Protein Oxidation and Reactive Oxygen Species Production. Journal of Alzheimer's Disease, 2000, 2, 123-131.	2.6	218
407	Effect of Exogenous and Endogenous Antioxidants on 3â€Nitropionic Acidâ€Induced⟨i⟩in vivo⟨ i⟩ Oxidative Stress and Striatal Lesions. Journal of Neurochemistry, 2000, 75, 1709-1715.	3.9	106
408	Vitamin î• as an Antioxidant/Free Radical Scavenger Against Amyloid β-Peptide-Induced Oxidative Stress in Neocortical Synaptosomal Membranes and Hippocampal Neurons in Culture: Insights into Alzheimer's Disease. Reviews in the Neurosciences, 1999, 10, 141-9.	2.9	84
409	Peroxynitrite-Induced Alterations in Synaptosomal Membrane Proteins. Journal of Neurochemistry, 1999, 72, 310-317.	3.9	147
410	In Vitro and in vivo Protein Oxidation Induced by Alzheimer's Disease Amyloid beta-Peptide (1-42). Annals of the New York Academy of Sciences, 1999, 893, 265-268.	3.8	24
411	The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease. Neurochemical Research, 1999, 24, 767-774.	3.3	90
412	The antioxidant vitamin E modulates amyloid beta-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochemical Research, 1999, 24, 427-435.	3.3	99
413	Aging in a dish: Age-dependent changes of neuronal survival, protein oxidation, and creatine kinase BB expression in long-term hippocampal cell culture. Journal of Neuroscience Research, 1999, 58, 308-317.	2.9	44
414	The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid beta-peptide (25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease. Neurochemical Research, 1998, 23, 1403-1410.	3.3	91

#	Article	IF	Citations
415	The Expression of Key Oxidative Stress-Handling Genes in Different Brain Regions in Alzheimer's Disease. Journal of Molecular Neuroscience, 1998, 11, 151-164.	2.3	117
416	Temporal Relations Among Amyloid \hat{l}^2 -Peptide-Induced Free-Radical Oxidative Stress, Neuronal Toxicity, and Neuronal Defensive Responses. Journal of Molecular Neuroscience, 1998, 11, 183-198.	2.3	55
417	Kinetics and Active Fraction Determination of a Protease Enzyme Immobilized on Functionalized Membranes: Mathematical Modeling and Experimental Results. Biotechnology Progress, 1998, 14, 865-873.	2.6	16
418	Structural and Functional Changes in Proteins Induced by Free Radical-mediated Oxidative Stress and Protective Action of the Antioxidants N-tert-Butyl-alpha-phenylnitrone and Vitamin Ea. Annals of the New York Academy of Sciences, 1998, 854, 448-462.	3.8	172
419	Adriamycin Induces Protein Oxidation in Erythrocyte Membranes. Basic and Clinical Pharmacology and Toxicology, 1998, 83, 62-68.	0.0	26
420	Amyloid β-peptide(1–40)-mediated oxidative stress in cultured hippocampal neurons. Journal of Molecular Neuroscience, 1998, 10, 181-192.	2.3	43
421	Bclâ€2 Protects Isolated Plasma and Mitochondrial Membranes Against Lipid Peroxidation Induced by Hydrogen Peroxide and Amyloid βâ€Peptide. Journal of Neurochemistry, 1998, 70, 31-39.	3.9	174
422	β-Amyloid-Associated Free Radical Oxidative Stress and Neurotoxicity:  Implications for Alzheimer's Disease. Chemical Research in Toxicology, 1997, 10, 495-506.	3.3	340
423	Chapter 7 Protein Oxidation Processes in Aging Brain. Advances in Cell Aging and Gerontology, 1997, 2, 161-191.	0.1	333
424	Oxidatively Induced Structural Alteration of Glutamine Synthetase Assessed by Analysis of Spin Label Incorporation Kinetics: Relevance to Alzheimer's Disease. Journal of Neurochemistry, 1997, 68, 2451-2457.	3.9	160
425	The Lipid Peroxidation Product, 4â€Hydroxyâ€2â€ <i>trans</i> Synaptosomal Membrane Proteins. Journal of Neurochemistry, 1997, 69, 1161-1169.	3.9	247
426	Amyloid β Peptide (25–35) Inhibits Na ⁺ â€Dependent Glutamate Uptake in Rat Hippocampal Astrocyte Cultures. Journal of Neurochemistry, 1996, 67, 277-286.	3.9	202
427	Prevention of Hyperoxiaâ€Induced Alterations in Synaptosomal Membraneâ€Associated Proteins by <i>Nâ€tert</i> àê€Butylâ€Î±â€Phenylnitrone and 4â€Hydroxyâ€2,2,6,6â€Tetramethylpiperidinâ€1â€oxyl (Tempol). Neurochemistry, 1996, 67, 2045-2050.	J o ⊕nal of	61
428	Amyloid β-peptide spin trapping I. NeuroReport, 1995, 6, 489-492.	1.2	50
429	\hat{l}^2 -Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer \hat{E} 1/4s disease. NeuroReport, 1995, 6, 1875-1879.	1.2	119
430	Flat-sheet and hollow fiber membrane bioreactors: A study of the kinetics and active site conformational changes of immobilized papain including sorption studies of reaction constituents. Journal of Chemical Technology and Biotechnology, 1995, 64, 157-164.	3.2	25
431	Interactions Between Carnosine and the Different Redox States of Myoglobin. Journal of Food Science, 1995, 60, 1201-1204.	3.1	62
432	A tombstone in Alzheimer's?. Nature, 1995, 373, 481-481.	27.8	54

#	Article	IF	Citations
433	Brain Regional Correspondence Between Alzheimer's Disease Histopathology and Biomarkers of Protein Oxidation. Journal of Neurochemistry, 1995, 65, 2146-2156.	3.9	682
434	Membrane Cytoskeletal Protein Alterations in Alzheimer's Disease. , 1995, , 78-94.		1
435	Biofunctional membranes Part IV. Active-site structure and stability of an immobilized enzyme, papain, on modified polysulfone membranes studied by electron paramagnetic resonance and kinetics. Journal of Membrane Science, 1994, 91, 47-64.	8.2	26
436	Optimization of covalently coupling enzymes to polymeric membranes: EPR studies of papain. Journal of Applied Polymer Science, 1993, 47, 1329-1342.	2.6	18
437	Interaction of tacrine and velnacrine with neocortical synaptosomal membranes: Relevance to Alzheimer's disease. Neurochemical Research, 1993, 18, 989-994.	3.3	12
438	Spin Labeling of Membrane Proteins in Mammalian Brain Synaptic Plasma Membranes: Partial Characterization. Analytical Letters, 1992, 25, 1201-1215.	1.8	27
439	Spin-Labelling Studies of the Interaction of 9-Amino-1,2,3,4-Tetrahydroacridine (Tha), A Proposed Drug for the Treatment of Alzheimer's Disease, with Erythrocyte Membranes. Free Radical Research Communications, 1990, 9, 361-366.	1.8	8
440	Water Transport Across Red-Cell Membranes Following Reductive Methylation of the Major Transmembrane Protein, Band 3: Implications to Increased Divalent Cation Membrane Permeability. Membrane Biochemistry, 1990, 9, 107-116.	0.6	О
441	Adenine and thymine grafts on polyethyleneimine. Journal of Polymer Science Part A, 1989, 27, 575-582.	2.3	2
442	Lipid Specific Spin-Labeling of Erythrocyte Membranes: Development and Characterization of a new Labeling Procedure for a Cationic Spin Label, CAT-16. Analytical Letters, 1988, 21, 1131-1140.	1.8	12
443	Evidence for an increased rate of choline efflux across erythrocyte membranes in Alzheimer's disease. Neurochemical Research, 1985, 10, 909-918.	3.3	18
444	2,2,6,6-Tetramethyl-4-Amino[d17]Piperidine-15N-1-OXYL as a Spin Label For Cell Surface Carbohydrates. Analytical Letters, 1985, 18, 555-561.	1.8	8
445	Reductive methylation of membrane proteins in human erythrocyte ghosts. Bioscience Reports, 1982, 2, 235-239.	2.4	2
446	Spin Labeling in Disease. , 1982, , 1-78.		77
447	Electron spin resonance study of membrane protein alterations in erythrocytes in Huntington's disease. Nature, 1977, 267, 453-455.	27.8	97
448	Spin label study of erythrocyte membrane fluidity in myotonic and Duchenne muscular dystrophy and congenital myotonia. Nature, 1976, 263, 159-161.	27.8	99